+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07408856

Evaluation of Intralesional CAN1012 Injection for Safety in Pre-Malignant Ductal and Lobular Carcinoma in Situ

Led by Providence Health & Services · Updated on 2026-09-24

24

Participants Needed

1

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CAN1012, an immune modulating drug, in patients diagnosed with ductal carcinoma in situ DCIS and lobular carcinoma in situ LCIS. This Phase IIb study aims to assess the safety of CAN1012 when injected directly into pre-malignant breast lesions prior to planned surgical removal. The study involves patients with specific tumor sizes and focuses on immunologic changes caused by the treatment. Participants receive a single intralesional injection of CAN1012 on Day 0. They are assigned to one of four study arms based on timing of surgery and clinical considerations. Each arm corresponds to surgery and tissue collection at different post-injection days 2-3, 5-7, 9-11, or 13-15 days. The study does not involve dose escalation and includes a 30-day post-operative safety follow-up period. During the study, participants undergo intralesional injection of CAN1012 followed by surgical resection of the lesion according to standard care. Tissue samples collected during surgery are evaluated for immune responses compared to baseline. Safety is monitored closely, including assessments 30 days after surgery. The study tracks participant disposition, treatment discontinuation, and withdrawal reasons over the course of participation.

CONDITIONS

Brief Title

CAN1012 in Pre-Malignant DCIS and LCIS

Research Team

I

Isa Ngirailemesang, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here